Annual CFF
$4.19 M
-$148.81 M-97.26%
31 December 2023
Summary:
Kymera Therapeutics annual cash flow from financing activities is currently $4.19 million, with the most recent change of -$148.81 million (-97.26%) on 31 December 2023. During the last 3 years, it has fallen by -$285.07 million (-98.55%). KYMR annual CFF is now -98.55% below its all-time high of $289.26 million, reached on 31 December 2020.KYMR Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$250.92 M
+$249.51 M+17670.40%
30 September 2024
Summary:
Kymera Therapeutics quarterly cash flow from financing activities is currently $250.92 million, with the most recent change of +$249.51 million (+17670.40%) on 30 September 2024. Over the past year, it has increased by +$251.12 million (+121904.85%). KYMR quarterly CFF is now -29.07% below its all-time high of $353.76 million, reached on 31 March 2024.KYMR Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$608.02 M
+$251.12 M+70.36%
30 September 2024
Summary:
Kymera Therapeutics TTM cash flow from financing activities is currently $608.02 million, with the most recent change of +$251.12 million (+70.36%) on 30 September 2024. Over the past year, it has increased by +$603.81 million (+14338.85%). KYMR TTM CFF is now at all-time high.KYMR TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KYMR Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -97.3% | +10000.0% | +10000.0% |
| 3 y3 years | -98.5% | +2.0% | +144.7% |
| 5 y5 years | -92.1% | - | - |
KYMR Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -98.5% | at low | -29.1% | >+9999.0% | at high | >+9999.0% |
| 5 y | 5 years | -98.5% | at low | -29.1% | >+9999.0% | at high | >+9999.0% |
| alltime | all time | -98.5% | at low | -29.1% | >+9999.0% | at high | >+9999.0% |
Kymera Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $250.92 M(>+9900.0%) | $608.02 M(+70.4%) |
| June 2024 | - | $1.41 M(-99.6%) | $356.90 M(+0.0%) |
| Mar 2024 | - | $353.76 M(>+9900.0%) | $356.79 M(+8411.2%) |
| Dec 2023 | $4.19 M(-97.3%) | $1.93 M(-1038.8%) | $4.19 M(-0.5%) |
| Sept 2023 | - | -$206.00 K(-115.8%) | $4.21 M(-97.3%) |
| June 2023 | - | $1.30 M(+12.6%) | $154.91 M(+0.6%) |
| Mar 2023 | - | $1.16 M(-40.7%) | $153.97 M(+0.6%) |
| Dec 2022 | $153.00 M | $1.95 M(-98.7%) | $153.00 M(-0.1%) |
| Sept 2022 | - | $150.50 M(>+9900.0%) | $153.10 M(-38.4%) |
| June 2022 | - | $364.00 K(+96.8%) | $248.64 M(-0.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $185.00 K(-91.0%) | $249.87 M(-0.2%) |
| Dec 2021 | $250.28 M(-13.5%) | $2.05 M(-99.2%) | $250.28 M(+0.7%) |
| Sept 2021 | - | $246.04 M(>+9900.0%) | $248.50 M(+25.0%) |
| June 2021 | - | $1.59 M(+167.6%) | $198.73 M(+1.0%) |
| Mar 2021 | - | $595.00 K(+120.4%) | $196.74 M(-32.0%) |
| Dec 2020 | $289.26 M(+728.6%) | $270.00 K(-99.9%) | $289.26 M(+0.1%) |
| Sept 2020 | - | $196.28 M(<-9900.0%) | $288.99 M(+211.7%) |
| June 2020 | - | -$403.00 K(-100.4%) | $92.72 M(-0.4%) |
| Mar 2020 | - | $93.12 M | $93.12 M |
| Dec 2019 | $34.91 M(-34.0%) | - | - |
| Dec 2018 | $52.93 M | - | - |
FAQ
- What is Kymera Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Kymera Therapeutics?
- What is Kymera Therapeutics annual CFF year-on-year change?
- What is Kymera Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Kymera Therapeutics?
- What is Kymera Therapeutics quarterly CFF year-on-year change?
- What is Kymera Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Kymera Therapeutics?
- What is Kymera Therapeutics TTM CFF year-on-year change?
What is Kymera Therapeutics annual cash flow from financing activities?
The current annual CFF of KYMR is $4.19 M
What is the all time high annual CFF for Kymera Therapeutics?
Kymera Therapeutics all-time high annual cash flow from financing activities is $289.26 M
What is Kymera Therapeutics annual CFF year-on-year change?
Over the past year, KYMR annual cash flow from financing activities has changed by -$148.81 M (-97.26%)
What is Kymera Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of KYMR is $250.92 M
What is the all time high quarterly CFF for Kymera Therapeutics?
Kymera Therapeutics all-time high quarterly cash flow from financing activities is $353.76 M
What is Kymera Therapeutics quarterly CFF year-on-year change?
Over the past year, KYMR quarterly cash flow from financing activities has changed by +$251.12 M (+121904.85%)
What is Kymera Therapeutics TTM cash flow from financing activities?
The current TTM CFF of KYMR is $608.02 M
What is the all time high TTM CFF for Kymera Therapeutics?
Kymera Therapeutics all-time high TTM cash flow from financing activities is $608.02 M
What is Kymera Therapeutics TTM CFF year-on-year change?
Over the past year, KYMR TTM cash flow from financing activities has changed by +$603.81 M (+14338.85%)